Track Belite Bio Inc American Depositary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Belite Bio Inc American Depositary Shares BLTE · Stock Open Belite Bio Inc American Depositary Shares in new tab

154.65 USD
EPS
-1.23
P/B
15.22
ROE
-41.44
Beta
-1.50
Target Price
56.75 USD
Loading chart...
Key Metrics
Earnings dateNov. 17, 2026
EPS-1.23
Book Value3.74
Price to Book15.22
% Insiders58.601%
Estimates
Forward P/E-59.32
Forward EPS-0.96
Target Mean Price56.75

DCF valuation

Model fair value for Belite Bio Inc American Depositary Shares (BLTE)
Result
Sign in to run the valuation for BLTE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 56.75 USD (low 50.00, high 60.00)
Low 50.00
Mean 56.75
High 60.00
Price 154.65
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Belite Bio Inc American Depositary Shares Logo Belite Bio Inc American Depositary Shares Analysis (BLTE)

United States Health Care Official Website Stock

Is Belite Bio Inc American Depositary Shares a good investment? Belite Bio Inc American Depositary Shares (BLTE) is currently trading at 154.65 USD. Market analysts have a consensus price target of 56.75 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Belite Bio Inc American Depositary Shares is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.96.

Investor FAQ

Does Belite Bio Inc American Depositary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is Belite Bio Inc American Depositary Shares?

Belite Bio Inc American Depositary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -1.23.

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Exchange Ticker
NMS (United States) BLTE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion